与胰腺癌新生血管有关的因子及其相关药物

The Factors Relative to Neo-angiogenesis of Pancreatic Adenocarcinoma and Correlated Drugs

综述与胰腺癌新生血管有关的生长调节因子及其相关药物的研究进展。胰腺癌患者的5年存活率较其他常见癌症患者低,而尚无有效的治疗方法和药物。目前有研究表明,抑制胰腺癌血管新生有可能成为治疗晚期胰腺癌的有效的治疗方法。在胰腺癌血管新生过程中,血管内皮生长因子、白细胞介素-8、转录因子NF-κB及C-蛋氨酸/肝细胞生长因子等扮演了重要的角色。因此,以这些调节因子作为靶点寻找合适的药物已成为晚期胰腺癌治疗的一个热点。

The five-year survival rate of patients with pancreatic adenocarcinoma is the lowest in cases with cancer. Moreover, there is not sufficient effective drugs or therapies for this adenocarcinoma. It is now becoming a hot spot to search for a better way for treatment of pancreatic adenocarcinoma in which the cancer neo-angiogenesis is inhibited by some proper drugs. The results of studies have indicated that some factors relative to cancer, such as VEGF, IL-8, NF-κB and c-Met/HGF, play an important role in growing process of neo-angiogenesis, which suggests that these facts may be the targets for drugs of treating pancreatic cancers. Based on literature, this article reviewed the factors relative to neo-angiogenesis of pancreatic adenocarcinoma and correlated valuable and prospective drugs in clinic.